An Open Label, Comparative, Randomized , Phase IV Pilot Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load
In HIV-infected people with metabolic fatty liver disease and liver fibrosis of any degree, as measured by non-invasive testing, antiretroviral treatment that includes rilpivinire for 18 months results in a slowing of progression and/or reduction of fatty metabolic liver disease, attenuating inflammation and liver fibrosis.
Phase IV, Randomized, Multicenter and Double Clinical Trial Blind Designed to Assess Safety and Convenience of the Change From DTG/3TC to BIC/FTC/TAF in People With HIV, Good Virological Control and Neuropsychiatric Vulnerabilities: MIND Study
In people infected with HIV, with suppressed HIV viral load and receiving treatment with DTG/3TC:
The change to BIC/FTC/TAF will decrease the development of adverse events of neuropsychiatric etiology.
The change to BIC/FTC/TAF may improve the patient´s tolerability and degree of acceptance and use of TAR.
Simplified Model of Linkage and Retention to Healthcare System, Using a Mobil Unit and a Same-day Test and Treat Approach Among Excluded Population.
Implementation of a model for access and retention of HIV care for vulnerable and excluded population using a mobile screening unit and a strategy of diagnosis and initiation of treatment with Bictegravir (BIC) 50 mg/ Emtricitabine (FTC) 200 mg / Tenofovir Alafenamide (TAF) 25 mg.
100 项与 SEIMC-GESIDA Foundation 相关的临床结果
0 项与 SEIMC-GESIDA Foundation 相关的专利（医药）
100 项与 SEIMC-GESIDA Foundation 相关的药物交易
100 项与 SEIMC-GESIDA Foundation 相关的转化医学
